Drug profile · INN
pralatrexate
FOLOTYN
pralatrexate (FOLOTYN) is a dihydrofolate reductase inhibitor. Associated with Mundipharma Pty Limited. Route of administration: injection. Current US regulatory status: approved.
Drug details — pralatrexate
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
pralatrexate (FOLOTYN) is a dihydrofolate reductase inhibitor. Associated with Mundipharma Pty Limited. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydrofolate reductase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | refused | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pralatrexate?
pralatrexate (FOLOTYN) is a dihydrofolate reductase inhibitor. Associated with Mundipharma Pty Limited. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for pralatrexate?
FOLOTYN is a marketed brand name for pralatrexate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pralatrexate?
pralatrexate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.